



# Innovative Payment Systems: England's MedTech Funding Mandate

Innovation, research and life sciences  
Transformation Directorate  
NHS England

**ACCELERATED  
ACCESS  
COLLABORATIVE**

The **AHSN** Network

# Our five priorities



## Research

Increase the speed, scale and diversity of the research in the NHS.



## Demand signalling and horizon scanning

Clearly identifying and articulating NHS needs and systematically searching for solutions.



## Uptake of proven innovation

Supporting the uptake of medicines, medical devices, diagnostics and digital products.



## Building innovation capacity

Supporting NHS organisations and workforce to develop, test and implement innovative solutions



## Innovator support

Making it easier to navigate innovation ecosystem and delivering transformational commercial deals at scale

# The MedTech Funding Mandate

The MedTech Funding Mandate is a NHS Long Term Plan commitment to get selected NICE-approved cost-saving devices, diagnostics and digital products to NHS patients more quickly

## Policy objectives



**Direct the NHS** on which NICE MTG and DG technologies are effective and cost saving by using assessment criteria



**Mandate commissioners** to fund supported technologies and providing NHS Payment System mechanism



**Simplify Procurement** by ensuring the technology is available on NHS Supply Chain



**Ensure equity** in healthcare provision by monitoring spread and adoption via data dashboards



**Support the NHS** to develop a sustainable approach to innovation adoption by commissioning the AHSN to support the policy implementation at the local level

## Product selection criteria

### Are effective

Demonstrated through positive NICE Medical Technology Guidance (MTG) or Diagnostic Guidance (DG)

### Are cost-saving in three years

NICE modelling demonstrates a net saving within three years

### Are affordable to the NHS

The cost impact should not exceed £20 million

To allow NHS healthcare providers ample time to plan and request funding, the MTG or DG guidance had to be published by NICE on or before 30 June to be assessed for support from 1<sup>st</sup> April the following year

# The MTFM supported technologies

Product	NICE Guidance	First year supported by MTFM
HeartFlow	<a href="#">MTG32</a>	2021/22
SecurAcath	<a href="#">MTG34</a>	
gammaCore	<a href="#">MTG46</a>	
Placental Growth Factor (PIGF) - based testing	<a href="#">DG23</a>	
UroLift	<a href="#">MTG58</a>	2022/23
Rezum	<a href="#">MTG49</a>	
GreenLight XPS	<a href="#">MTG29</a>	
The PLASMA System (TURis)	<a href="#">MTG53</a>	
Thopaz+	<a href="#">MTG37</a>	
XprESS multi-sinus dilation system	<a href="#">MTG30</a>	
Spectra Optia	<a href="#">MTG28</a>	